Special Meeting Scheduled for June 29,
2021
Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I,
a Delaware corporation (“the Company”) (Nasdaq: RACA) announced
today that its registration statement on Form S-4 (File Number
333-254600) (as amended, the “Registration Statement”), relating to
the previously announced business combination (the “Business
Combination”) with POINT Biopharma Inc. (“POINT”), has been
declared effective by the U.S. Securities and Exchange Commission
(“SEC”) and that it will commence mailing a definitive proxy
statement/prospectus relating to the Special Meeting (the “Special
Meeting”) of the Company’s stockholders to be held on June 29, 2021
in connection with the Business Combination. The proxy
statement/prospectus is being mailed to the Company’s stockholders
of record as of the close of business on June 4, 2021 (the “Record
Date”). Notice of the Special Meeting will be mailed on or about
June 9, 2021 to stockholders of record as of the Record Date.
About POINT Biopharma
POINT Biopharma is a globally focused radiopharmaceutical
company building a platform for the clinical development and
commercialization of radioligands that fight cancer. POINT is
combining a portfolio of best-in-class radiopharmaceutical assets,
a seasoned management team, strategic partnerships in radioisotope
supply, manufacturing technology and novel direct-to-patient
targeting to revolutionize theragnostic drug development and
radioligand commercialization. Learn more at
https://www.pointbiopharma.com.
About Therapeutics Acquisition Corp, d/b/a Research Alliance
Corp. I
Research Alliance Corp. I is sponsored by RA Capital Management,
L.P., and is led by Chairman and CEO Peter Kolchinsky, PhD and CFO
Matthew Hammond, PhD. Research Alliance Corp. I is a blank check
company formed for the purpose of effecting a business combination
with one or more businesses in the healthcare industry.
About RA Capital Management
RA Capital is a multi-stage investment manager dedicated to
evidence-based investing in public and private healthcare and life
science companies that are developing drugs, medical devices, and
diagnostics. The flexibility of its strategy allows RA Capital to
provide seed funding to startups and to lead private, IPO, and
follow-on financings for its portfolio companies, allowing
management teams to drive value creation from inception through
commercialization.
Important Information About the Business Combination and
Where to Find It
A full description of the terms of the Business Combination is
provided in a registration statement on Form S-4 filed with the SEC
by Therapeutics Acquisition Corp. d/b/a/ Research Alliance Corp. I.
(“RACA”) which includes a prospectus with respect to the combined
company’s securities to be issued in connection with the Business
Combination and a proxy statement with respect to the Special
Meeting at which the shareholders of RACA will vote on the Business
Combination. RACA urges its investors, shareholders and other
interested persons to read the definitive proxy statement/
prospectus relating to the Special Meeting as well as other
documents filed with the SEC because these documents will contain
important information about RACA, POINT and the Business
Combination. The definitive proxy statement/prospectus relating
to the Special Meeting will be mailed to shareholders of RACA as of
the close of business on June 4, 2021, the record date for the
Special Meeting. Shareholders are also be able to obtain a copy of
the S-4, including the proxy statement/prospectus, and other
documents filed with the SEC without charge, by directing a request
to: Research Alliance Corp. I, Attn: Secretary, 200 Berkeley St,
18th floor, Boston, MA 02116. The definitive proxy
statement/prospectus relating to the Special Meeting can also be
obtained, without charge, at the SEC’s website (www.sec.gov).
Participants in the Solicitation
RACA and POINT and their respective directors and executive
officers may be considered participants in the solicitation of
proxies with respect to the proposed business combination described
in this press release under the rules of the SEC. Information about
the directors and executive officers of RACA is set forth in RACA’s
final prospectus for initial public offering filed with the SEC
pursuant to Rule 424(b) of the Securities Act of 1933, as amended
(the “Securities Act”) on July 9, 2020, and is available free of
charge at the SEC’s website at www.sec.gov or by directing a
request to: Research Alliance Corp. I, Attn: Secretary, 200
Berkeley St, 18th floor, Boston, MA 02116. Information regarding
the persons who may, under the rules of the SEC, be deemed
participants in the solicitation of the RACA shareholders in
connection with the proposed business combination will be set forth
in the registration statement containing the proxy
statement/prospectus for the proposed business combination when it
is filed with the SEC. These documents can be obtained free of
charge from the sources indicated above.
Non-Solicitation
This press release is not a proxy statement or solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the proposed business combination and shall not
constitute an offer to sell or a solicitation of an offer to buy
any securities nor shall there be any sale of securities in any
state or jurisdiction in which such offer, solicitation, or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. No offer of
securities shall be made except by means of a prospectus meeting
the requirements of the Securities Act.
Forward-Looking Statements
This press release contains forward-looking statements that are
based on beliefs and assumptions and on information currently
available. In some cases, you can identify forward-looking
statements by the following words: “may,” “will,” “could,” “would,”
“should,” “expect,” “intend,” “plan,” “anticipate,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,”
“ongoing” or the negative of these terms or other comparable
terminology, although not all forward-looking statements contain
these words. These statements involve risks, uncertainties and
other factors that may cause actual results, levels of activity,
performance or achievements to be materially different from the
information expressed or implied by these forward-looking
statements. Although we believe that we have a reasonable basis for
each forward-looking statement contained in this press release, we
caution you that these statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. Forward-looking
statements in this press release include, but are not limited to,
statements regarding the proposed business combination, including
the timing and structure of the business combination, the proceeds
from the business combination, the initial market capitalization of
the combined company and the benefits of the business combination,
as well as statements about the potential attributes and benefits
of POINT’s product candidates and the format and timing of POINT’s
product development activities and clinical trials. We cannot
assure you that the forward-looking statements in this press
release will prove to be accurate. These forward-looking statements
are subject to a number of significant risks and uncertainties that
could cause actual results to differ materially from expected
results, including, among others, the ability to complete the
business combination due to the failure to obtain approval from
RACA’s shareholders or satisfy other closing conditions in the
business combination agreement, the occurrence of any event that
could give rise to the termination of the business combination
agreement, the outcome of any legal proceedings that may be
instituted against RACA or POINT following announcement of the
proposed business combination and related transactions, the impact
of COVID-19 on POINT’s business and/or the ability of the parties
to complete the business combination, the ability to obtain or
maintain the listing of RACA’s common stock on Nasdaq following the
proposed business combination, costs related to the proposed
business combination, changes in applicable laws or regulations,
the possibility that RACA or POINT may be adversely affected by
other economic, business, and/or competitive factors, and other
risks and uncertainties, including those included under the header
“Risk Factors” in the registration statement on Form S-4 filed by
RACA with the SEC and those included under the header “Risk
Factors” in the final prospectus of RACA related to its initial
public offering. Most of these factors are outside of RACA’s and
POINT’s control and are difficult to predict. Furthermore, if the
forward-looking statements prove to be inaccurate, the inaccuracy
may be material. In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements
as a representation or warranty by us or any other person that we
will achieve our objectives and plans in any specified time frame,
or at all. The forward-looking statements in this press release
represent our views as of the date of this press release. We
anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we have no
current intention of doing so except to the extent required by
applicable law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210609005898/en/
RACA Contact: Matthew Hammond Chief Financial Officer
(617) 778-2540
POINT Contact: Ari Shomair VP, Corporate Affairs
media@pointbiopharma.com (647) 812-2417
Investor Relations Contact: Alex Lobo Stern Investor
Relations investors@pointbiopharma.com
Therapeutics Acquisition (NASDAQ:RACA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Therapeutics Acquisition (NASDAQ:RACA)
Historical Stock Chart
From Oct 2023 to Oct 2024